| Item type |
デフォルトアイテムタイプ（フル）fmu(1) |
| 公開日 |
2022-04-15 |
| タイトル |
|
|
タイトル |
Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer |
|
言語 |
en |
| 作成者 |
Sugimoto, Mitsuru
Takagi, Tadayuki
Suzuki, Rei
Konno, Naoki
Asama, Hiroyuki
Sato, Yuki
Irie, Hiroki
Okubo, Yoshinori
Nakamura, Jun
Takasumi, Mika
Hashimoto, Minami
Kato, Tsunetaka
Kobashi, Ryoichiro
Hikichi, Takuto
Ohira, Hiromasa
|
| 権利情報 |
|
|
権利情報Resource |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
|
権利情報 |
© 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. However, as oxaliplatin and paclitaxel are common neurotoxic drugs, chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse effect of both treatments. As there are no agents recommended in the ASCO guidelines, we review the methods used to treat CIPN caused by PC treatment. The efficacy of duloxetine was observed in a large randomized controlled trial (RCT). In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs. Although duloxetine and pregabalin can be effective for CIPN, they have several side effects. Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future. |
| 出版者 |
|
|
出版者 |
The Fukushima Society of Medical Science |
| 言語 |
|
|
言語 |
eng |
| 書誌情報 |
en : Fukushima Journal of Medical Science
巻 68,
号 1,
p. 1-10,
発行日 2022
|
| 関連情報 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.5387/fms.2021-32 |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
35197393 |
| 関連情報 |
|
|
|
識別子タイプ |
ICHUSHI |
|
|
関連識別子 |
2023116777 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0016-2590 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2185-4610 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA0065246X |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Peripheral neuropathy |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Chemotherapy |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Pancreatic cancer |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Oxaliplatin |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Paclitaxel |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Nab-paclitaxel |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Antineoplastic Agents |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Duloxetine Hydrochloride |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Humans |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Oxaliplatin |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Paclitaxel |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Pancreatic Neoplasms |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Peripheral Nervous System Diseases |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Pregabalin |
| 主題 |
|
|
主題Scheme |
MeSH |
|
主題 |
Randomized Controlled Trials as Topic |
FksmJMedSci_68_p1.pdf (246.2 KB)
